#	Pagina
attuale pagina	/open-h2020/projects/225119/index.html
-1	/open-h2020/projects/221256/results.html
-2	/open-h2020/per-topic/rwc/list/index.html

Opendata, web and dolomites

StaphIMPACT SIGNED

SA.100: Next-generation targeted antibacterial product entering European market

Total Cost €

EC-Contrib. €

Partnership

Views

StaphIMPACT project word cloud

Explore the words cloud of the StaphIMPACT project. It provides you a very rough idea of what is the project "StaphIMPACT" about.

care eczema antibiotics company capacity syndrome profitability 1 ige ideas prepares resistant communication 8b secured 7 aggravated health launched kills bacteria claiming companies gladskin final kill time caused diabetic smei hyper 100 us unless dermatology deaths resistance 2024 employment aureus owns 2023 markets biggest trillion soft sa brand million market 177b antibiotic 2018 ip full staphylococcus helping chosen threats compounds driving infections thousands life 10 rosacea inflammatory stakeholders first expressed endolysin extra 2050 cagr world changing facilities according roll indications mrsa cosmetics contribution netherlands alternatives develops humanity produces innovation regardless triggered clinical pharma skin micreos small cancer antibacterial 19 acne people wound suffering license replace kols

Project "StaphIMPACT" data sheet

The following table provides information about the project.

Coordinator	MICREOS HUMAN HEALTH BV Organization address address: BANKAPLEIN 2 city: S GRAVENHAGE postcode: 2585EV website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Total cost	3˙565˙625 €
EC max contribution	2˙495˙937 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2019
Duration (year-month-day)	from 2019-07-01 to 2021-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	MICREOS HUMAN HEALTH BV MICREOS HUMAN HEALTH BV Organization address address: BANKAPLEIN 2 city: S GRAVENHAGE postcode: 2585EV website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (S GRAVENHAGE)	coordinator	2˙495˙937.00

Map

Project objective

According to the WHO, antibiotic resistance is one of humanity’s biggest health threats, claiming ~10 million extra deaths per year and US$100 trillion by 2050, unless alternatives to antibiotics are developed. Micreos has developed the world’s first targeted antibacterial products, set to replace antibiotics. With its endolysin technology, for the first time it is possible to kill only the unwanted bacteria, regardless of resistance. Micreos’ endolysin technology was chosen as Europe’s most relevant Innovation 2018 (Ideas from Europe). Its first lead endolysin, SA.100, kills only Staphylococcus aureus, including the resistant MRSA. Soft-launched under the Gladskin brand in the Netherlands, it’s having life-changing impact for thousands of people with inflammatory skin conditions caused or aggravated by S. aureus, including eczema, acne, rosacea and Hyper IgE syndrome. Micreos also develops products for diabetic wound infections and a skin cancer triggered by S. aureus. Micreos owns all relevant IP and know-how on its technology and produces its compounds and Gladskin products at small-scale at its facilities in the Netherlands. With this SMEi, Micreos prepares for full roll-out into the EU markets of its SA.100/Gladskin. This includes scale-up of production capacity, strengthening clinical evidence and communication of results to KOLs and relevant stakeholders. Leading pharma and cosmetics companies have expressed interest to in-license Micreos’ technology for particular indications. Relevant markets are the consumer’s skin care market ($177b by 2024; CAGR 4.7%) and dermatology market ($19.8b by 2023; CAGR 9.1%.). Own contribution by Micreos for this SMEi is already secured. This SMEi enables Micreos to take final steps for EU-wide roll-out, driving employment growth and company profitability, and helping people suffering from inflammatory skin conditions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STAPHIMPACT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STAPHIMPACT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

AUTHEVOO (2019)

DNA-Authenticity & Traceability for Extra Virgin Olive Oil: Τrust the DNA, the label.

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.